- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03492658
Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)
August 16, 2022 updated by: Hans Ulrich Scherer, Leiden University Medical Center
Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA).
To investigate the effect of CTLA4-Ig (abatacept) on phenotype, transcriptional profile, B cell receptor usage and functional parameters of circulating B cells expressing anticitrullinated protein antibodies (ACPA) in patients with early, methotrexate-naïve, ACPA positive rheumatoid arthritis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
B cells expressing anti citrullinated protein antibodies (ACPA) in patients with rheumatoid arthritis (RA) display an activated, proliferative phenotype.
Experimental data indicate that ACPA and ACPA-expressing B cells are actively involved in driving the disease process in RA.
The present study is based on the hypothesis that targeted intervention with CTLA4-Ig (abatacept) as a means to interfere with T cell help for B cells in early, active, ACPA-positive rheumatoid arthritis can reverse the activated, proliferative phenotype of citrullinated antigen-specific B cells.
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leiden, Netherlands
- Leiden University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Each patient must:
- have a diagnosis of rheumatoid arthritis according to the revised 2010 EULAR/ACR criteria for classification of RA
- have a positive test for the presence of anti-citrullinated protein antibodies (ACPA) in serum as determined by routine clinical assay.
- have adequate hematologic function (ANC ≥ 4000 cells/μL, platelet count ≥ 150000/μL, and hemoglobin ≥ 10 g/dL (corresponding to 6.2 mmol/L)
- have serum creatinine concentrations < 1.5 mg/dl and/or a normal creatinine clearance
- if a female patient is of childbearing potential, agree to: comply with effective contraceptive measures, use adequate contraception since the last menses, use adequate contraception during the study, have a negative pregnancy test within one week of study entry
- be willing to receive a booster vaccination against tetanus toxoid three to four weeks prior to randomization
- be able and willing to give written informed consent prior to entry in the study
Exclusion Criteria:
Any patient who has:
- been previously treated with either abatacept and/or methotrexate or another csDMARD
- been previously treated with a kinase inhibitor
- been previously treated with rituximab or another B-cell depleting agent
- been previously treated with a biological DMARD
- received intra-articular or systemic glucocorticoid injections or has required treatment for acute RA flare (not being part of a regular therapeutic regimen) within four weeks prior to randomization or requires narcotic analgesics other than those accepted by the investigator for analgesia (e.g. paracetamol, codeine, tramadol)
- been tested negative for anti citrullinated protein antibodies
- contraindications for a booster vaccination against tetanus toxoid prior to randomization to the treatment arms; if a patient refuses booster vaccination but has detectable numbers of tetanus toxoid-specific B cells circulating in peripheral blood prior to the baseline visit, the patient can still be allowed to participate in the study at the judgement of the investigator.
- evidence of any other major chronic inflammatory disease (i.e. psoriasis, psoriatic arthritis, spondyloarthritis or inflammatory bowel disease)
- evidence of poorly controlled diabetes, history of clinically significant pulmonary disease including interstitial lung disease or methotrexate-induced lung disease, poorly controlled asthma or a history of severe life-threatening asthma attacks, history of active tuberculosis, history of latent tuberculosis without adequate medical treatment, liver cirrhosis or fibrosis, significant active infection or any underlying diseases that could predispose the subject to infections
- liver function abnormality (total bilirubin ≥ 1.5x the upper limit of normal range, AST, ALT ≥ 3x upper limit of normal range)
- concurrent treatment with an experimental drug or who has participated in another clinical trial with an investigational drug within 30 days prior to study entry
- pre-existing sensory or motor polyneuropathy ≥ Grade 2 according to NCI CTC
- past or current history of neoplasms, except for curatively treated non-melanoma skin cancer, adequately treated in situ carcinoma of the cervix or another cancer curatively treated and with no evidence of disease for at least 10 years
- significant cardiac disease, cardiac arrhythmia (Lown Grade ≥ III), uncontrolled hypertension or recent history of myocardial ischemia
- pregnant or nursing women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination therapy (MTX/abatacept)
Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
|
Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
Other Names:
Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
|
Active Comparator: Methotrexate (MTX) monotherapy
Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
|
Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of ACPA-expressing B cells that express the marker Ki-67
Time Frame: 24 weeks
|
Flow cytometry-based determination of the percentage of ACPA-expressing B cells that stain positive for Ki-67, circulating in peripheral blood of patients with early, ACPA-positive rheumatoid arthritis.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in disease activity
Time Frame: 24 weeks
|
The change from baseline in disease activity (expressed as DAS 44).
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients achieving remission
Time Frame: 12, 24, 36 and 48 weeks
|
To evaluate the percentage of patients achieving SDAI remission.
|
12, 24, 36 and 48 weeks
|
Monitor treatment-related immunological serum/plasma markers
Time Frame: Each study visit: baseline + 12, 24, 36 and 48 weeks
|
to monitor treatment-related immunological serum/plasma markers (rheumatoid factor (IgM), anti-citrullinated protein antibodies and antibodies against other posttranslational modified proteins (AMPAs), anti-tetanus toxoid antibodies, IgG, IgA, IgM, and phenotypic cellular markers on circulating lymphocytes.
|
Each study visit: baseline + 12, 24, 36 and 48 weeks
|
Change of expression level the marker Ki-67
Time Frame: 12, 36 and 48 weeks
|
Evaluate the change of expression level (from baseline) of the marker Ki-67 on memory B cells expressing ACPA versus memory B cells specific for recall antigens (tetanus toxoid) in peripheral blood.
|
12, 36 and 48 weeks
|
Change in serum/plasma parameters related to disease activity
Time Frame: 12, 24, 36 and 48 weeks
|
Evaluate the change from baseline in serum/plasma parameters related to disease activity (e.g.
erythrocyte sedimentation rate, C-reactive protein, interleukin-6, -8, -10, TNF-alpha, vascular endothelial growth factor, granulocyte-monocyte colony stimulating factor).
|
12, 24, 36 and 48 weeks
|
Change of expression level of the markers CD80, CD86 and HLA-DR
Time Frame: 12, 24, 36 and 48 weeks
|
Evaluate the change of expression level (from baseline) of the markers CD80, CD86 and HLA-DR on memory B cells expressing ACPA versus memory B cells specific for recall antigens (tetanus toxoid) in peripheral blood.
|
12, 24, 36 and 48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hans Ulrich Scherer, Leiden University Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Willemze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol. 2012 Jan 31;8(3):144-52. doi: 10.1038/nrrheum.2011.204.
- Keating GM. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jul;73(10):1095-119. doi: 10.1007/s40265-013-0080-9.
- Kerkman PF, Fabre E, van der Voort EI, Zaldumbide A, Rombouts Y, Rispens T, Wolbink G, Hoeben RC, Spits H, Baeten DL, Huizinga TW, Toes RE, Scherer HU. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Jun;75(6):1170-6. doi: 10.1136/annrheumdis-2014-207182. Epub 2015 Jun 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 17, 2018
Primary Completion (Actual)
October 26, 2021
Study Completion (Actual)
April 6, 2022
Study Registration Dates
First Submitted
April 3, 2018
First Submitted That Met QC Criteria
April 3, 2018
First Posted (Actual)
April 10, 2018
Study Record Updates
Last Update Posted (Actual)
August 17, 2022
Last Update Submitted That Met QC Criteria
August 16, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Rheumatic Diseases
- Collagen Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Immune Checkpoint Inhibitors
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
- Abatacept
Other Study ID Numbers
- NL62584.058.17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatic Diseases
-
Xijing HospitalAir Force Military Medical University, ChinaUnknownRheumatic Valve DiseaseChina
-
Assiut UniversityNot yet recruitingRheumatic Mitral Valve Disease
-
Paris Cardiovascular Research Center (Inserm U970)Not yet recruitingRheumatic Heart Disease in Children
-
Duke UniversityChildhood Arthritis and Rheumatology Research AllianceRecruitingRheumatic Joint DiseaseUnited States, Canada, Israel, Italy, Puerto Rico
-
Assiut UniversityRecruitingFollow up of Moderate Aortic Regurge After Rheumatic Mitral Valve ReplacementEgypt
-
Children's National Research InstituteUniversity of Cape Town; Thrasher Research Fund; Murdoch Childrens Research Institute and other collaboratorsUnknownHeart Diseases | Rheumatic Heart Disease | Rheumatic Heart Disease in Children | Latent Rheumatic Heart DiseaseUganda
-
Centre Hospitalier Universitaire de NiceCompleted
-
Ettore Sansavini Health Science FoundationUnknownTricuspid (Valve) Insufficiency (Rheumatic)Italy
-
University Hospital Inselspital, BerneInstituto de Cardiología Paredes-Horna, Arequipa; Hospital Nacional Carlos...CompletedRheumatic Heart Disease | Acute Rheumatic FeverPeru, Switzerland
-
University Hospital Inselspital, BerneRecruitingRheumatic Heart Disease | Rheumatic Heart Disease in ChildrenNepal
Clinical Trials on Abatacept
-
Bristol-Myers SquibbCompletedUlcerative ColitisUnited States, Australia, India, Korea, Republic of, Poland, Canada, France, Brazil, Mexico, Puerto Rico, Belgium, Switzerland, Italy, Netherlands, Germany, Ireland, South Africa, United Kingdom, Czech Republic
-
University Medical Center GroningenBristol-Myers SquibbCompletedSjögren's SyndromeNetherlands
-
Melbourne HealthNational Health and Medical Research Council, Australia; Juvenile Diabetes...Active, not recruitingDiabetes Mellitus, Type 1 | Type 1 DiabetesAustralia
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedMultiple Sclerosis, Relapsing-RemittingUnited States, Canada
-
Rüdiger B. MüllerBristol-Myers SquibbCompletedRheumatoid ArthritisSwitzerland
-
Karolinska InstitutetKing's College Hospital NHS Trust; Institute of Rheumatology, PragueCompletedDermatomyositis | PolymyositisSweden, Czechia
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted